RxDoctor Payments Data

Jay Kumar, MD

Pulmonary Disease · Brooksville, FLNPI 1427161215

Payments from drug & device makers

$5,272in general payments, 2019–2025

Across 55 payments — averaging $95.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Pulmonx Corporation$869
  • Intuitive Surgical$704
  • Medtronic$554
  • Alphatec Spine, Inc$348
  • AstraZeneca$250
  • plus $870 from 9 others

What the payments were for

  • Travel & lodging$2,65150%
  • Food & beverage$2,62150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,272 in reported general payments places this provider in the 50th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$160,788
Medicare patients
425
Services billed
1,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol337$182,864
Trelegy ElliptaFluticasone/Umeclidin/Vilanter231$182,145
Spiriva RespimatTiotropium Bromide118$92,126
Stiolto RespimatTiotropium Br/Olodaterol Hcl110$62,025
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr106$54,762
Combivent RespimatIpratropium/Albuterol Sulfate56$46,313
Fluticasone-SalmeterolFluticasone Propion/Salmeterol174$30,958
SymbicortBudesonide/Formoterol Fumarate45$15,898
Wixela InhubFluticasone Propion/Salmeterol102$14,060
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,992
Albuterol Sulfate HfaAlbuterol Sulfate322$8,879
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium14$8,578
Incruse ElliptaUmeclidinium Bromide13$7,760
Clarithromycin36$7,341
BreynaBudesonide/Formoterol Fumarate67$5,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort, Breztri Aerosphere$250$27,89062 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Brooksville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →